NGS for Drug Development
Proven NGS Technology to Support Pharmaceutical Development
Illumina provides an innovative portfolio of next-generation sequencing (NGS) systems, products, and services for the drug development pipeline. With solutions to inform the drug development process, you can confidently choose us as a partner from discovery through companion diagnostics development.
NGS approaches can generate multiple levels of genomic data essential for drug development, from genomic modifications to transcriptome profiling and quantification, epigenetic modifications, and more.
We are uniquely positioned to deliver products and services to support pharmaceutical development with the largest install base of NGS instrumentation.
Approximately 90 percent of all sequencing data produced today has been generated using Illumina technologies*. Reference and service labs are installing our instruments in increasing numbers to perform a wide variety of applications.
Illumina Drug Discovery and Development Solutions
The Illumina portfolio informs multiple stages of the drug discovery and pharmaceutical development process, from target identification to post approval.
Click on the below to view methods and products supporting the various drug discovery and development stages.
Whole-Genome Sequencing (WGS)
Take a comprehensive view of the genomic variation linked to a pathway.
Whole-Exome SequencingExplore genomic variation in the protein-coding regions of the genome as a cost-effective alternative to WGS.
RNA SequencingCharacterize expression by sequencing individual targets or the entire transcriptome.
Cancer Sequencing MethodsPerform whole-genome studies, targeted gene profiling, tumor-normal comparisons, ctDNA sequencing, and more.
TruSight Oncology 500 Product FamilyEnabling comprehensive genomic profiling from both blood and tissue samples.
Immuno-Oncology ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.
Drug Response RNA Biomarker Discovery
Learn how to use RNA-Seq to identify novel RNA-based drug response biomarkers.
EpigeneticsFind NGS and microarray tools to study epigenetic modifications and their impact on gene regulation.
Sequencing PlatformsFind the sequencing system that best fits your scale of study.
Bioinformatics ToolsUser-friendly tools to guide you from experimental design to data interpretation and reporting.
Genomic ServicesFind an Illumina service provider to support your genomics needs.
Cancer Sequencing Methods
Perform whole-genome studies, targeted gene profiling, tumor-normal comparisons, ctDNA sequencing, and more.
TruSight Oncology 500 Product FamilyEnabling comprehensive genomic profiling from both blood and tissue samples.
Cancer RNA SequencingConfirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples. Or leverage RNA-Seq to discover and profile RNA-based drug response biomarkers.
Immuno-Oncology ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment
Sequencing Platforms
Find the sequencing system that best fits your scale of study.
InformaticsUser-friendly tools guide you from experimental design to data interpretation and reporting.
Genomic ServicesFind an Illumina service provider to support your genomics needs.
Cancer Sequencing Methods
Perform whole-genome studies, targeted gene profiling, tumor-normal comparisons, ctDNA sequencing, and more.
TruSight Oncology 500 Product FamilyEnabling comprehensive genomic profiling from both blood and tissue samples.
Cancer RNA SequencingConfirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples. Or leverage RNA-Seq to discover and profile drug response RNA biomarkers.
Immuno-Oncology ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.
Sequencing Platforms
Find the sequencer that best fits your scale of study.
InformaticsUser-friendly tools guide you from experimental design to data interpretation and reporting.
Genomic ServicesFind an Illumina service provider to support your genomics needs.
Explore our unique, multi-analyte approach to co-development.
Cancer Sequencing MethodsPerform whole-genome studies, targeted gene profiling, tumor-normal comparisons, ctDNA sequencing, and more.
TruSight Oncology 500 Product FamilyEnabling comprehensive genomic profiling from both blood and tissue samples.
Cancer RNA SequencingConfirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples.
Immuno-Oncology ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.
Sequencing Platforms
Find the sequencer that best fits your scale of study.
Companion Diagnostics DevelopmentExplore our unique, multi-analyte approach to co-development.
High-Throughput Genotyping Research ToolsGain meaningful insights from complex populations.
InformaticsUser-friendly tools guide you from experimental design to data interpretation and reporting.
Genomic ServicesFind an Illumina service provider to support your genomics needs.
Companion Diagnostic Development
Explore our unique, multi-analyte approach to co-development.
MiSeqDx InstrumentDiscover the first FDA-cleared next-generation sequencing system.
NextSeq 550Dx InstrumentExplore the next level in diagnostic power for the clinical lab.
High-Throughput Genotyping Research Tools
Gain meaningful insights from complex populations.
Genomic ServicesFind an Illumina service provider to support your genomics needs.
Exclusive Offer for TruSight Oncology 500
Purchase the TruSight Oncology 500 assay for the first time and receive an exclusive limited time offer.
Learn More
Scientists Discuss Drug Discovery Projects
Value of a Panomics-Based Drug Discovery Approach
Integrating imaging, multiomic technologies, and big data uncovers novel diagnostic and therapeutic targets for common chronic diseases.
Read Interview
Beyond Single-Drug Approaches to Precision Oncology
Researchers utilize transcriptomics to uncover multiple drug-susceptible tumorigenic pathways.
Read Interview
Advancing Drug Discovery with Microbiome Studies
Whole-genome shotgun sequencing and transcriptomics provide pharmaceutical scientists with data to refine drug discovery and development.
Read InterviewComprehensive Molecular & Immune Profiling for Drug Development
Dr. Jeffrey Conroy, Chief Scientific Officer of OmniSeq, Inc., discusses the value of combining genomic and immune profiling. He also showcases the impact of a scalable comprehensive assay and infrastructure in the context of drug development.
View Webinar
Related Solutions
Cancer
NGS-based methods allow cancer researchers to detect rare somatic variants, tumor subclones, and circulating DNA fragments. Learn more about cancer genomics.
Microbiology
From metagenomics and microbiome studies to infectious disease surveillance, NGS can help researchers gain genetic insight into bacteria and viruses. Learn more about microbial genomics.
Complex Diseases
Sequencing is introducing new avenues for understanding autoimmune diseases, atherosclerosis, neurological diseases, and psychiatric disorders on a molecular level. Learn more about complex disease genomics.
Rare Diseases
NGS can help scientists uncover genetic variants associated with rare and undiagnosed disorders. Learn more about rare disease genomics.
Interested in receiving newsletters, case studies, and information on genomics in drug development? Enter your email address.
Additional Resources
NGS Used for Biological QC in BioPharma Production
Read how Merck Serono uses NGS for cell line stability testing and biosafety monitoring.
RNA-Seq for Drug Response Biomarker Discovery and Profiling
Access resources to explore NGS-based biomarker discovery and profiling.
Polygenic Risk Scores
Polygenic risk scores represent the total number of genetic variants that an individual has to assess their heritable risk of developing a particular disease.
Scaling NGS to Deliver Discoveries
Regeneron discusses their latest work and overall mission to explore new variations in genomes that can help explain disease.
* Data calculations on file. Illumina, Inc. 2017.